Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma. 2009

Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Osaka, Japan. fujisan@dent.osaka-u.ac.jp

BACKGROUND Boron neutron capture therapy (BNCT) is a selective radiotherapy, being effective for the treatment of even advanced malignancies in head and neck regions as well as brain tumors and skin melanomas. To clarify the role of p53 gene, the effect of BNCT on oral squamous cell carcinoma (SCC) cells showing either wild- (SAS/neo) or mutant-type (SAS/mp53) p53 was examined. METHODS Cells were exposed to neutron beams in the presence of boronophenylalanine (BPA) at Kyoto University Research Reactor. Treated cells were monitored for modulations in colony formation, proliferation, cell cycle, and expression of cell cycle-associated proteins. RESULTS When SAS/neo and SAS/mp53 cells were subjected to BNCT, more suppressive effects on colony formation and cell viability were observed in SAS/neo compared with SAS/mp53 cells. Cell cycle arrest at the G1 checkpoint was observed in SAS/neo, but not in SAS/mp53. Apoptotic cells increased from 6 h after BNCT in SAS/neo and 48 h in SAS/mp53 cells. The expression of p21 was induced in SAS/neo only, but G2 arrest-associated proteins including Wee1, cdc2, and cyclin B1 were altered in both cell lines. CONCLUSIONS These results indicate that oral SCC cells with mutant-type are more resistant to BNCT than those with wild-type p53, and that the lack of G1 arrest and related apoptosis may contribute to the resistance. At a physical dose affecting the cell cycle, BNCT inhibits oral SCC cells in p53-dependent and -independent manners.

UI MeSH Term Description Entries
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011836 Radiation Tolerance The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS. Radiation Sensitivity,Radiosensitivity,Sensitivity, Radiation,Tolerance, Radiation,Radiation Sensitivities,Radiation Tolerances,Radiosensitivities,Sensitivities, Radiation,Tolerances, Radiation
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016754 Boron Neutron Capture Therapy A technique for the treatment of neoplasms, especially gliomas and melanomas in which boron-10, an isotope, is introduced into the target cells followed by irradiation with thermal neutrons. Boron-Neutron Capture Therapy,Neutron Capture Therapy, Boron,Therapy, Boron Neutron Capture,Therapy, Boron-Neutron Capture

Related Publications

Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
January 2006, International journal of radiation biology,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
May 2004, Oral oncology,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
May 1997, Journal of neuro-oncology,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
February 2008, Radiation and environmental biophysics,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
January 2021, International journal of radiation biology,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
October 2019, Military Medical Research,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
November 1989, Nihon geka hokan. Archiv fur japanische Chirurgie,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
July 1997, The British journal of radiology,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
January 2000, Anticancer research,
Yusei Fujita, and Itsuro Kato, and Soichi Iwai, and Koji Ono, and Minoru Suzuki, and Yoshinori Sakurai, and Ken Ohnishi, and Takeo Ohnishi, and Yoshiaki Yura
March 1994, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!